TF and cancer: Whereas TF or procoagulatory parts of the molecule retargeted to tumors with different molecular constructs and within multiple studies in the last 20 years have shown promising anti-tumor activity in various preclinical models, none of the molecules studied have been consequently developed into an investigational new product (IMP) for clinical application in cancer patients.